Brief: Panbela Presents Clinical Data On Phase 1B Clinical Trial Of Sbp-101 In Combination With Gemcitabine And NAB-Paclitaxel
24/01/2022 14:33
Jan 24 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA PRESENTS CLINICAL DATA ON PHASE 1B CLINICAL TRIAL
OF
SBP-101 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN
PATIENTS WITH METASTATIC PDA AT 2022 ASCO GI MEETING
Source text for Eikon: ID:nGNX10ZzzB
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants